Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
NUWE Transcript
Nuwellis, Inc. (NUWE) Q3 2025 Earnings Call Prepared Remarks Transcript
Unknown11-12
The earnings call reveals several challenges: a 6% revenue decline, reduced gross margins, increased operating expenses, and a higher operating loss. Despite some positive aspects like sequential revenue growth and a focus on U.S. market expansion, the termination of international operations and dependency on the U.S. market pose risks. The cash position is limited, and manufacturing transition risks exist. With no new partnerships or positive shareholder return plans discussed, the overall sentiment is negative, likely leading to a -2% to -8% stock price movement.
Nuwellis, Inc. (NUWE) Q2 2025 Earnings Call Transcript
Unknown8-14
The earnings call presents a mixed picture. While there is growth in pediatrics and improved reimbursement for heart failure, the overall financial performance is concerning. Revenue declined by 21% due to a product back order, and margins fell significantly. The termination of the REVERSE-HF trial and increased net losses further add to the negative sentiment. Despite the resolution of the sterilization issue and potential in pediatrics, the financial challenges and operational risks outweigh the positives, leading to a negative outlook for the stock.
Nuwellis, Inc. (NASDAQ:NUWE) Q1 2025 Earnings Call Transcript
Unknown5-14
The earnings call reveals mixed signals. While there are positive developments like increased reimbursement rates and outpatient market entry, there are concerns about declining international sales, margin reduction, and customer dependency risks. The Q&A section highlighted some unresolved issues, such as the lack of clarity on revenue drops and vague timelines for clinical trials. Despite financial improvements in operating loss and expenses, the absence of a share repurchase program and manufacturing challenges temper expectations. Overall, these factors suggest a neutral impact on the stock price over the next two weeks.
Nuwellis, Inc. (NUWE) Q1 2025 Earnings Call Transcript
Unknown5-13
The earnings call presents mixed signals. Positive factors include new account wins, outpatient market entry, increased reimbursement rates, and operating loss improvements. However, these are offset by declining international sales, customer dependency risks, reduced gross margins, and lack of clear guidance in the Q&A. The absence of a share repurchase program and a decrease in cash position further contribute to a neutral outlook. Given these factors, the stock is likely to remain stable within a -2% to 2% range over the next two weeks.
NUWE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
